David A. Siegel Protalix Bio Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.37 - $2.16 $959 - $1,512	-700 Reduced 3.4%	19,900 $41,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $1.37 $4,794 - $6,439	-4,700 Reduced 18.58%	20,600 $28,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.24 $49,822 - $59,980	-48,371 Reduced 65.66%	25,300 $26,000
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.56 $15,066 - $23,042	14,771 Added 25.08%	73,671 $80,000
Q1 2022 May 16, 2022	SELL	$0.81 - $1.17 $33,210 - $47,970	-41,000 Reduced 41.04%	58,900 $62,000

Q4 2021 Feb 14, 2022	BUY	$0.81 - $1.33 $69,417 - $113,981	85,700 Added 603.52%	99,900 $83,000
Q3 2021 Nov 15, 2021	BUY	$1.31 - $1.87 $18,602 - $26,554	14,200 New	14,200 $19,000

9.27M

40.6K

10.1K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $53.7M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.